NVS - RayzeBio Is A New Contender in Radiopharmaceutical Arena Will Attract Prominent Entities: JP Morgan | Benzinga
JP Morgan has initiated coverage on RayzeBio Inc (NASDAQ: RYZB), representing a pure-play opportunity in the radiopharmaceutical space.
Analysts Jessica Fye, Nick Lenard, and Na Sun see a relatively de-risked lead asset in RYZ101 currently in phase 3 and an earlier-stage pipeline that could offer further long-term value.
JP Morgan has initiated with an Outperform rating and a price target of $30.
The analysts see the radiopharmaceuticals space still in ...